AAD Guidelines: Awareness of Comorbidities Associated with Atopic Dermatitis in Adults
Date of Original Release: December 8, 2023
Date of Expiration: December 8, 2026
Estimated Time of Completion: 60 minutes
Target Audience
Dermatologists and others involved in the delivery of dermatologic care.
Statement of Need
The American Academy of Dermatology bases its CME activities on identified professional practice gaps, the educational needs which underlie these gaps, and emerging clinical research findings as these relate to dermatology. Learners should reflect upon clinical and scientific information presented in this CME activity and determine the need for further study.
Learning Objectives
Following participation in this activity, the learner should be able to:
- Recognize the prevalent comorbidities associated with atopic dermatitis in adults.
- Implement strategies to manage the potential impact of comorbidities associated with atopic dermatitis in adults.
- Inform clinical decision-making thereby improving practice gaps in atopic dermatitis management.
- Recognize known gaps and barriers in care for comorbidities associated with Atopic dermatitis (AD).
- Identify performance indicators, associated tools, and resources which aid in the assessment and improvement of the quality of AD comorbidities.
- Describe the role of the dermatologist in addressing the gaps in care among treating comorbidities associated with AD.
Accreditation Statement
The American Academy of Dermatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA PRA Credit Statement
The American Academy of Dermatology designates this Enduring Material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Instructions to Claim Credit
To Claim CME credit for this activity, the learner must achieve a 70% passing score on the post-test and complete the post-activity evaluation survey.
Planners
Steven Daveluy, MD, FAAD
Wayne State University
Detroit, MI
Aaron Drucker, MD, FAAD
University of Toronto
Toronto, ON CA
Mona El-Shamaa, MPH
Manager, Quality Improvement
American Academy of Dermatology
Rosemont, IL
Lindsy Frazer-Green, MS, PhD
Senior Manager, Clinical Practice Guidelines & Research
American Academy of Dermatology
Rosemont IL
Sameer Malik, MD, MBA
Associate Director, Science & Research
American Academy of Dermatology
Rosemont, IL
Laura Vera, MSW, LSW, LSSGB
Associate Director, Quality Innovations
American Academy of Dermatology
Rosemont, IL
Speakers
Steven Daveluy, MD, FAAD
Wayne State University
Detroit, MI
Aaron Drucker, MD, FAAD
University of Toronto
Toronto, ON CA
Reviewers
Mona El-Shamaa, MPH
Manager, Quality Improvement
American Academy of Dermatology
Rosemont, IL
Lindsy Frazer-Green, MS, PhD.
Senior Manager, Clinical Practice Guidelines & Research
American Academy of Dermatology
Rosemont IL
Staff:
Dustin Herlich, MA
Manager, Digital Learning
American Academy of Dermatology
Rosemont, IL
Melinda Keske
Senior Coordinator, Digital Learning
American Academy of Dermatology
Rosemont, IL
Christine Presta, BS, FACEHP
Director, Digital Learning
American Academy of Dermatology
Rosemont, IL
Camilia Schawel, MMeD
Instructional Designer
American Academy of Dermatology
Rosemont, IL
Disclosures
All planners, speakers, reviewers, and staff for this activity have no relevant financial relationships with ineligible companies (formerly known as commercial interests).
Conflict Mitigation Statement
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the American Academy of Dermatology has implemented mechanisms, prior to the planning implementation of this activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content.
Unapproved Use Disclosure
The American Academy of Dermatology requires CME faculty/authors to disclose to learners when products or procedures are being discussed are off-label (not approved for the indications being discussed), unlabeled (not approved for any indications), experimental and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these products/procedures. If you have questions, contact the medical affairs department of the manufacturer for the most recent approval information. Faculty/authors of this activity may be discussing information about pharmaceutical agents that is outside of the U.S. Food and Drug Administration approved labeling.
Disclaimer
The American Academy of Dermatology (AAD) is not responsible for statements made by the author(s). Statement or opinions expressed in this activity reflect the views of the author(s) and do not reflect the official policy of the AAD. The information provided in this CME activity is for continuing education purposes only, is not intended to establish a standard of care, and is not meant to substitute for independent medical judgment of a health provider relative to the diagnostic, management and treatment options of a specific patient’s medical condition.
No Medical Advice
The information in this publication by the American Academy of Dermatology or any third party should not be considered medical advice and is not intended to replace consultation with a qualified dermatology professional. The American Academy of Dermatology does not answer specific medical questions or refer people to a particular dermatology professional.
Contact Information
For the American Academy of Dermatology Member Resource Center, please call (866) 503-7546.